ArticleAllergy & rhinology (Providence, R.I.)2017
Long-term omalizumab use in the treatment of exercise-induced anaphylaxis.
Article in Allergy & rhinology (Providence, R.I.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Getting in Shape: Updates in Exercise Anaphylaxis.Current allergy and asthma reports · 2024Review
- Uneventful vaginal delivery using epidural anesthesia in patient with exercise induced anaphylaxis: a case report and literature review.Nagoya journal of medical science · 2024Review
- A case report of food-dependent exercise-induced anaphylaxis (FDEIA) treated with omalizumab.Frontiers in allergy · 2024Article
- The management of exercise-induced anaphylaxis in a Chinese child with biologics: a case report.Frontiers in allergy · 2024Article
- Severe exercise-induced anaphylaxis in a hot and humid area successfully treated with omalizumab: a case report.Frontiers in allergy · 2023Article
- Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
- The Role of KIT Mutations in Anaphylaxis.Current allergy and asthma reports · 2019Review
- Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study.Frontiers in pharmacology · 2019Article
- Exercise-Induced Anaphylaxis: Literature Review and Recent Updates.Current allergy and asthma reports · 2018Review
- Two decades with omalizumab: what we still have to learn.Biologics : targets & therapy · 2018Review
- A survey of anaphylaxis etiology and treatment.Medical gas researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed. He was refractory to these medications and continued to have episodes of EIA. He was then started on a trial of omalizumab, an immunoglobulin E monoclonal antibody, and had resolution of the EIA episodes. After discontinuation of the omalizumab, the EIA episodes returned. He was restarted on omalizumab and since that time, has had 5 years free of EIA episodes and can now exercise without any symptoms. To our knowledge, this is only the third case in the literature of successful treatment of EIA by using omalizumab. This case was unique because it provided successful long-term use of omalizumab for EIA. Further studies are recommended for the use of omalizumab in the treatment of EIA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.